Partnering

Curasight is building a pipeline of products based on its use of the uPAR Theranostics platform which combines improved diagnosis of certain types of cancer using uTRACE® and more targeted and efficient treatment of the tumor using its therapeutic uTREAT® product.

In 2023 we signed a partnership for prostate cancer with the leading global radiopharmaceuticals company Curium Inc. Under the deal Curasight develops its proprietary uTRACE^® technology for use in prostate cancer until regulatory approval in the EU and USA, with Curium responsible for the commercial manufacture of uTRACE^® and world-wide commercialization. Curasight is eligible to receive up to mUSD 70 in development and commercial milestones as well as double-digit percentage royalties on sales in major markets upon eventual commercialization.

We are committed to pursuing our goals through strategic partnerships industry and academic players. Please contact: CEO Ulrich Krasilnikoff for further details email: [email protected]